Pfizer Inc (NYSE:PFE) has gone ahead to make the much awaited news. It was a moment of great excitement after the European Commission (EC) gave approval to Trumenba vaccine, which the company is said to have directed so much in terms of resources to come up with. According to some top officials working with the top provider, the Trumenba vaccine will aid active immunization of persons aged 10 years and over. The Company is considering using its approved product to prevent the wide array of the invasive diseases caused by Neisseria meningitidis serogroup B (MenB).

The marketing authorization has already expressed its willingness to help Pfizer proceed with the move to commercialize the vaccine. Of course the commercialization will be done in all European Union (EU) member states, along with Norway, Iceland and Liechtenstein. Sources indicate that at this particular moment marketing activities for the vaccine have already taken root in the U.S.

To reach its decision, the European Commission (EC) is said to have taken a close look at data from one of the clinical development programs. It evaluated about 20,000 adolescents and adults in the hope that it would help it come up with the best decision.

Data obtained from the study according to some top experts demonstrated established safety profile for Trumenba, which is known to induce protective serum bactericidal antibody responses to the wide range of MenB test strains.

The two- and three-dose schedules associated with the drug according to some top researchers in a great way aid in the administration of the vaccine in close consideration to the respective individuals’ risk of susceptibility and exposure to MenB.

In a recent press conference, one of the top executives working with Pfizer outlined that nearly 60% of the meningococcal disease cases occurring in Europe were sparked about by serogroup B. He went ahead to state that it was not an easy task diagnosing Meningococcal disease. The official added that it was even trickier getting to distinguish it from the less serious and common diseases such as flu. Lives continue to be lost regardless to the fact that antibiotics have been made available to the various patients.